Thông tin thuốc gốc
Chỉ định và Liều dùng
Acute malaria
Adult: Initially, 800 mg, then 400 mg after 6-8 hr and a further 400 mg once daily for 2 succeeding days. Alternatively, 800 mg as single dose.
Child: Initially, 13 mg/kg as single dose then 6.5 mg/kg after 6, 24 and 48 hr.

Discoid lupus erythematosus, RA (rheumatoid arthritis), Systemic lupus erythematosus
Adult: Initially, 400 mg daily as single or in 2 divided doses. Maintenance: 200-400 mg daily, according to response. Max: 6.5 mg/kg/day or 400 mg daily, whichever is lower.
Child: Up to 6.5 mg/kg daily or 400 mg daily, whichever is lower.

Prophylaxis of malaria
Adult: Initially, 400 mg once wkly, 2 wk before exposure and continued until 8 wk after exposure. Alternatively, if 2-wk lead-in period is not possible, 800 mg as loading dose in 2 divided doses 6 hr apart, then 400 mg once wkly continued until 8 wk after exposure. All doses should be taken on same day of each wk.
Child: 6.5 mg/kg once wkly, 2 wk before exposure and continued until 8 wk after exposure. Alternatively, if 2-wk lead-in period is not possible, 13 mg/kg as loading dose in 2 divided doses 6 hr apart, then once wkly treatment for 8 wk after exposure. All doses should be taken on same day of each wk.
Cách dùng
Should be taken with food.
Chống chỉ định
Pre-existing maculopathy of the eye.
Thận trọng
Patient w/ G6PD deficiency, DM, haematological and GI disorders, alcoholism, porphyria, psoriasis. Renal and hepatic impairment. Childn. Pregnancy and lactation.
Tác dụng không mong muốn
Significant: Cardiomyopathy (e.g. AV block, pulmonary HTN, sick sinus syndrome), myocardial toxicity, QT interval prolongation, ventricular arrhythmia, torsade de pointes; skin reactions; bone marrow suppression (e.g. agranulocytosis, anaemia, aplastic anaemia, leucopenia, thrombocytopenia); proximal myopathy or neuromyopathy leading to progressive weakness, proximal muscle atrophy, depressed tendon reflexes, abnormal nerve conduction. Rarely, suicidal behaviour; keratopathy, retinopathy.
Nervous: Ataxia, dizziness, emotional disturbance, emotional lability, headache, irritability, lassitude, nerve deafness, nervousness, nightmares, psychosis, seizures, vertigo.
GI: Anorexia, diarrhoea, nausea, stomach cramps, vomiting.
Resp: Bronchospasm.
Hepatic: Acute hepatic failure. Rarely, hepatic insufficiency.
Endocrine: Exacerbation of porphyria, wt loss.
Haematologic: Haemolysis in G6PD deficiency.
Ophthalmologic: Accommodation disturbance, corneal changes (e.g. transient oedema, punctuate to linear opacities, decreased sensitivity, deposits, visual disturbances, blurred vision, photophobia), decreased visual acuity, macular oedema, nystagmus, optic disk disorder, retinal pigment changes, retinal vascular disease, retinitis pigmentosa, scotoma, vision color changes, visual field defect.
Otic: Tinnitus.
Dermatologic: Acute generalised exanthematous pustulosis, alopecia, bleaching of hair, bullous rash, dyschromia, annulare centrifugum erythema, erythema multiforme, exacerbation of psoriasis, exfoliative dermatitis, lichenoid eruption, maculopapular rash, morbilliform rash, pruritus, skin photosensitivity, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria, purpuric rash.
Immunologic: Hypersensitivity reactions (e.g. angioedema).
Potentially Fatal: Cardiac failure, severe hypoglycaemia.
Thông tin tư vấn bệnh nhân
This drug may cause dizziness and blurred vision, if affected, do not drive or operate machinery.
Chỉ số theo dõi
Monitor for signs/symptoms of cardiac compromise; CBC, serum glucose, proximal muscle strength and reflexes, LFT, renal function. Perform baseline and periodic eye examination.
Quá liều
Symptoms: Headache, visual disturbances, CV collapse, convulsions, and hypokalaemia. Rhythm and conduction disorders, including QT prolongation, Torsades de Pointes, ventricular tachycardia and ventricular fibrillation, followed by sudden potentially fatal resp and cardiac arrest. Management: Symptomatic and supportive treatment. Perform gastric lavage or emesis immediately. Activated charcoal can be introduced into the stomach by tube following lavage w/in 30 min of ingestion, given in a dose at least 5 times of the overdose to inhibit further absorption. Administer diazepam IV to reverse cardiotoxicity. Resp support and shock management should be instituted as needed.
Tương tác
Hydroxychloroquine may enhance the effect of hypoglycaemic agents. May increase plasma digoxin level. Increased risk of Torsades de pointes w/ QTc-prolonging agents (e.g. disopyramide, quinidine, amiodarone, sotalol, cisapride). Increased risk of convulsion w/ mefloquine. Antacids may interfere w/ hydroxychloroquine absorption.
Tác dụng
Description: Hydroxychloroquine is a 4-aminoquinoline derivative. It interferes w/ parasite digestive vacuoles by increasing pH and interfering w/ parasite’s ability to metabolise and utilise erythrocyte Hb. The mechanism of action in the treatment of rheumatoid arthritis and lupus erythematosus has not been fully elucidated.
Absorption: Rapidly and completely absorbed. Time to peak plasma concentration: 1.83 hr.
Distribution: Widely distributed in the body. Crosses the placenta and enters breast milk (small amounts). Plasma protein binding: Approx 40%, mainly to albumin.
Metabolism: Metabolised in the liver into desethylhydroxychloroquine and desethylchloroquine (major metabolites) and small amount of bisdesethylchloroquine.
Excretion: Via urine (15-25% as metabolites, ≤60% as unchanged drug). Elimination half-life: Approx 40 days.
Đặc tính

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Hydroxychloroquine, CID=3652, https://pubchem.ncbi.nlm.nih.gov/compound/Hydroxychloroquine (accessed on Jan. 23, 2020)

Bảo quản
Store between 20-25°C. Protect form light.
Phân loại MIMS
Thuốc chống sốt rét / Thuốc chống thấp khớp có cải thiện bệnh trạng
Phân loại ATC
P01BA02 - hydroxychloroquine ; Belongs to the class of aminoquinoline antimalarials.
Tài liệu tham khảo
Anon. Hydroxychloroquine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 28/06/2017.

Buckingham R (ed). Hydroxychloroquine Sulfate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 28/06/2017.

Joint Formulary Committee. Hydroxychloroquine Sulfate. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 28/06/2017.

McEvoy GK, Snow EK, Miller J et al (eds). Hydroxychloroquine Sulfate. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 28/06/2017.

Plaquenil (Sanofi-Aventis Australia Pty Ltd). TGA eBusiness Services Product and Consumer Medicine Information. https://www.ebs.tga.gov.au. Accessed 28/06/2017.

Plaquenil 200mg FC Tabs (Zentiva). eMC. https://www.medicines.org.uk/emc/. Accessed 28/06/2017.

Plaquenil 200mg Film-Coated Tablets (Winthrop Pharmaceuticals UK Limited). MHRA. https://products.mhra.gov.uk/. Accessed 28/06/2017.

Plaquenil Tablet (Concordia Pharmaceuticals Inc). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 28/06/2017.

Plaquenil Tablet Film Coated (Sanofi-Aventis US LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 28/06/2017.

Rossi S (ed). Hydroxychloroquine. Australian Medicines Handbook [online]. Adelaide. Australian Medicines Handbook Pty Ltd. https://amhonline.amh.net.au. Accessed 28/06/2017.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Hydroxychloroquine từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2022 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
  • Plaquenil
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in